Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899833 | 0.87 | SOAT1 (0.38) | ALDH1A1HSD17B10LMNATDP1SOAT1 | |
| SCHEMBL29110368 | 0.83 | SOAT1 (0.40) | ALDH1A1HSD17B10LMNATDP1SOAT1 | |
| SCHEMBL27676719 | 0.81 | FFAR3 (0.35) | ALDH1A1SOAT1CYP2C9 | |
| SCHEMBL30829428 | 0.80 | — | — | |
| SCHEMBL21811739 | 0.80 | ALDH1A1 (0.33) | ALDH1A1HSD17B10LMNASOAT1CYP2C9 | |
| SCHEMBL30590452 | 0.80 | ALDH1A1 (0.36) | ALDH1A1TSHRHSD17B10LMNASOAT1 | |
| SCHEMBL10571663 | 0.80 | — | — | |
| SCHEMBL5613333 | 0.80 | — | — | |
| SCHEMBL27437384 | 0.79 | SOAT1 (0.32) | ALDH1A1LMNASOAT1CYP2C9 | |
| SCHEMBL11649825 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TSHRHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108484613-B | Pyrazolo [1,5-a ] pyrimidine compound and application thereof | 江南大学 | 2020-07-07 | — | — | CN | disclosed |
| CN-104981470-A | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | Bayer Pharma AG | 2015-10-14 | — | — | CN | disclosed |
| US-8779086-B2 | Electrochromic material and a method for producing the same | KURARAY CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20130172571-A1 | PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| US-20130005941-A1 | ELECTROCHROMIC MATERIAL AND A METHOD FOR PRODUCING THE SAME | KURARAY CO., LTD. (JP) | 2013-01-03 | — | — | US | disclosed |
| WO-2012032528-A2 | IMPROVED PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172571-A1 | PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | FIP1L1, UMPS, UBXN4 | ALDH1A1 434/4885TSHR 3369/4885HSD17B10 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.